Dr. Cheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
Bronx, NY 10467Phone+1 718-920-4826Fax+1 718-920-8543
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2009 - 2012
- UMass Chan Medical SchoolResidency, Internal Medicine, 2006 - 2009
- Hunan Medical UniversityClass of 1997
Certifications & Licensure
- NY State Medical License 2009 - 2025
Clinical Trials
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Publications & Presentations
PubMed
- 1 citationsLung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).David Kozono, Xing Hua, Michael C Wu, Khaled A Tolba, Saiama N Waqar
Journal of Thoracic Oncology. 2024-08-05 - 1 citationsAurora Kinase A Inhibition Potentiates Platinum and Radiation Cytotoxicity in Non-Small-Cell Lung Cancer Cells and Induces Expression of Alternative Immune Checkpoints.Huijie Liu, Ayse Ece Cali Daylan, Jihua Yang, Ankit Tanwar, Alain Borczuk
Cancers. 2024-08-09 - 94 citationsTargeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatmentHaiying Cheng, Marina Shcherba, Gopichand Pendurti, Yuanxin Liang, Bilal Piperdi
Lung Cancer Management. 2014-01-01
Press Mentions
- Update 2020: Management of Non-Small Cell Lung CancerNovember 11th, 2020
- Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN StudyDecember 13th, 2023
- First-Line Immunotherapy Benefits Patients of All Races with NSCLC EquallyDecember 24th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: